Compare MLM & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | NTRA |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 29.1B |
| IPO Year | 1996 | 2015 |
| Metric | MLM | NTRA |
|---|---|---|
| Price | $565.61 | $219.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $689.36 | $259.07 |
| AVG Volume (30 Days) | 510.5K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ 25.06 | N/A |
| Revenue | ★ $6,150,000,000.00 | $210,939,000.00 |
| Revenue This Year | $13.76 | $18.08 |
| Revenue Next Year | $7.98 | $19.65 |
| P/E Ratio | $22.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $525.38 | $131.81 |
| 52 Week High | $710.97 | $256.36 |
| Indicator | MLM | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 56.79 |
| Support Level | $554.72 | $186.96 |
| Resistance Level | $629.63 | $222.53 |
| Average True Range (ATR) | 16.05 | 10.04 |
| MACD | 1.02 | 1.01 |
| Stochastic Oscillator | 57.96 | 76.92 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.